HIV, PrEP, PrEP Adherence
Conditions
Keywords
PrEP, Adherence, Oral PrEP, Injectable cabotegravir
Brief summary
The LYPS intervention is a multi-level intervention that combines: a) structural-level delivery of PrEP and PrEP services by a community health professional (CHP) at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van), with b) an individual-level mobile application (app) to support PrEP adherence and persistence between CHP visits.
Detailed description
LYPS is a two-arm randomized controlled trial (RCT) to assess the efficacy of the LYPS intervention. Up to 272 participants will be randomized in a 1:1 ratio to receive either the LYPS intervention or enhanced standard of care (eSOC) (136 participants per arm). The eSOC control condition will consist of usual clinic-based PrEP care and access to a limited number of LYPS app components. Participants will complete four research assessments, at Enrollment and Weeks 12, 24, and 36, that include computer-assisted self-interviews (CASIs) and blood collection. CASIs will collect information including, but not limited to, demographics, PrEP adherence and persistence, PrEP clinic visit attendance, PrEP knowledge and attitudes, PrEP self-efficacy, PrEP stigma, and psychosocial variables, questions that evaluate components of the LYPS intervention, tailored for intervention and eSOC conditions. Blood (dried blood spot \[DBS\] and plasma) will be collected to evaluate PrEP drug concentrations and stored for additional study-related testing. All participants will receive daily oral PrEP, oral PrEP taken using a 2-1-1 dosing strategy, or injectable PrEP based on their preference and in consultation with their PrEP provider. There is no randomization involved for PrEP provision and participants are allowed to switch between oral and injectable PrEP or vice versa during the study. PrEP care visits (quarterly for those on oral PrEP and two monthly injections followed by an injection every two months for those on injectable PrEP) will include clinical labs such as HIV and STI testing and focused physical exams for signs and symptoms of HIV infection. Other relevant clinical data collected as part of the participant's PrEP clinical care will also be collected.
Interventions
OTHERLYPS
The LYPS intervention combines the use of a CHP to deliver PrEP services at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van) with an android-based smartphone or iphone app to support PrEP use between CHP visits.
OTHEREnhanced Standard of Care
Clinic-based PrEP services per usual standard of care (e.g., HIV and STI testing, clinical assessments for signs and symptoms of HIV and PrEP safety) with access to a limited number of LYPS app components, including basic PrEP adherence information and study visit reminders.
Sponsors
Westat
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institutes of Health (NIH)
Florida State University
The Emmes Company, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Participants will be randomized in a 1:1 ratio to receive either the LYPS intervention or eSOC. The LYPS intervention arm consists of structural-level delivery of PrEP and PrEP services by a community health professional (CHP) at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van) with an individual-level mobile application to support PrEP adherence and persistence between CHP visits. The eSOC control condition consists of usual clinic-based PrEP care and access to a limited number of LYPS app components.
Eligibility
Sex/Gender
ALL
Age
13 Years to 24 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 13-24 years, inclusive; * Reports anal or vaginal sex in the past year; * Is not living with HIV; * Weighs at least 35 kilograms (77 pounds); * Willing to receive PrEP care from a provider at a participating SC either in the clinic or at one of the designated places in the community being offered by the SC SC; * Has an Android-based smartphone or iPhone; * Has fluency in English (able to read, speak, and understand English); and * Willing to provide informed consent to participate in the study.
Exclusion criteria
* Has counter-indications for PrEP according to guidelines and approved local label; * Has any clinically significant systemic disease (including but not limited to significant or uncontrolled liver disease, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis, or bone disease) or diabetes; * Any other medical, behavioral, or other conditions that, in the opinion of the SC project lead or designee, could interfere with adherence to study procedures or compromise interpretation of study results; * Concurrent participation in ATN 166, ATN 170, or any other clinical trial providing HIV medications (PrEP, vaccine, etc.) or currently receiving any PrEP-adherence or persistence behavioral intervention; or * Is currently incarcerated or pending incarceration.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PrEP adherence at 6 months | 6 months | Determine adherence outcomes as measured by blood will be tailored for oral PrEP modality (daily oral or 2-1-1) and target vs. non-target PrEP concentration thresholds (depending on regimen) will be examined. Adherence outcomes for participants on injectable PrEP will be determined by the timely (± 1 week for the second injection; ± 2 weeks for any subsequent injection) administration of injections. |
| PrEP persistence at 6 months | 6 months | Access persistence measures as based on 1) participant's self-report of currently taking PrEP (daily or 2-1-1) or having received last shot of injectable PrEP, and 2) has an active prescription for PrEP based on study records or drug level associated with use at 6 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PrEP adherence at 9 months | 9 months | Determine adherence outcomes as measured by blood will be tailored for oral PrEP modality (daily oral or 2-1-1) and target vs. non-target PrEP concentration thresholds (depending on regimen) will be examined. Adherence outcomes for participants on injectable PrEP will be determined by the timely (± 1 week for the second injection; ± 2 weeks for any subsequent injection) administration of injections. |
| PrEP persistence at 9 months | 9 months | Access persistence measures as based on 1) participant's self-report of currently taking PrEP (daily or 2-1-1) or having received last shot of injectable PrEP, and 2) has an active prescription for PrEP based on study records or drug level associated with use at 9 months. |
Countries
United States
Contacts
CONTACTNancy Liu
CONTACTErin Ricketts
STUDY_CHAIRKate Muessig
Florida State University
STUDY_CHAIRKeith Horvath
San Diego State University
STUDY_CHAIRAudrey Pettifor
UNC Chapel Hill
PRINCIPAL_INVESTIGATORLisa Hightow-Weidman, MD, MPH
Florida State University
PRINCIPAL_INVESTIGATORSybil Hosek, PhD
University of Illinois at Chicago
Outcome results
None listed